Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) VP Robert E. Waltermire sold 14,113 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $341.32, for a total value of $4,817,049.16. Following the transaction, the vice president now directly owns 3,728 shares in the company, valued at approximately $1,272,440.96. This trade represents a 79.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Madrigal Pharmaceuticals Price Performance
Shares of MDGL traded up $2.64 during trading hours on Friday, hitting $331.41. 419,416 shares of the stock were exchanged, compared to its average volume of 440,970. The company has a market cap of $7.32 billion, a price-to-earnings ratio of -13.21 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. Madrigal Pharmaceuticals, Inc. has a 12-month low of $189.00 and a 12-month high of $377.46. The stock’s 50-day moving average price is $324.17 and its two-hundred day moving average price is $287.02.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.32) by $1.61. The firm had revenue of $103.32 million during the quarter, compared to analysts’ expectations of $97.81 million. Research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
MDGL has been the topic of a number of recent analyst reports. Citigroup raised their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright raised their target price on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. B. Riley upgraded Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and boosted their target price for the company from $236.00 to $422.00 in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $375.75.
Read Our Latest Analysis on MDGL
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Read More
- Five stocks we like better than Madrigal Pharmaceuticals
- The Significance of Brokerage Rankings in Stock Selection
- Is Myers Industries Poised for a Breakout?
- The 3 Best Retail Stocks to Shop for in August
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- How Can Investors Benefit From After-Hours Trading
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.